Form 4: Apollomics COO Yi-Kuei Chen Reports RSU Vesting

Apollomics Chief Operating Officer Yi-Kuei Chen acquired 5,000 Class A Ordinary Shares through the vesting of restricted stock units.

Summary

• Chief Operating Officer Yi-Kuei Chen acquired 5,000 Class A Ordinary Shares on June 15, 2026.
• The acquisition resulted from the vesting of restricted stock units (RSUs).
• Following the transaction, the reporting person holds 15,000 shares directly.
• The reporting person maintains an indirect interest in 101,248 shares through Maxpro Investment Co., Ltd.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as it represents the standard fulfillment of an existing executive compensation agreement.

Positives

• The transaction reflects the vesting of equity compensation, aligning the executive's interests with long-term shareholder value.

Negatives

• None identified.

Risks

• The reporting person disclaims beneficial ownership of shares held by Maxpro Investment Co., Ltd. except to the extent of his pecuniary interest.

Future Outlook

The filing notes that an additional 5,000 shares are scheduled to vest on September 15, 2026.

Industry Context

StockSavvy.ai notes that routine RSU vesting for C-suite executives in the biotechnology sector is standard practice and generally does not signal a change in strategic direction or market sentiment.

Comparison to Industry Standards

• The transaction follows standard equity compensation vesting schedules common among publicly traded biotech firms.
• The reporting structure is consistent with SEC requirements for Section 16 officers.

Related Party Transactions

• The reporting person is a member of the Board of Directors of Maxpro Investment Co., Ltd. and co-founder/managing director of Maxpro Ventures Ltd.

Stakeholder Impact

• Minimal impact on shareholders as this is a routine equity vesting event.

Next Steps

• Vesting of an additional 5,000 shares scheduled for September 15, 2026.

Key Dates

Keywords

Apollomics, APLM, Insider Trading, Form 4, Equity Compensation, Biotech